Gene Editing Drug Halves Harmful Cholesterol in Early Trials
TL;DR Summary
A Phase 1 clinical trial demonstrated that a single infusion of a CRISPR-based gene-editing drug targeting the ANGPTL3 gene can reduce harmful LDL cholesterol and triglycerides by about half, offering a potential permanent solution for high cholesterol, though long-term safety remains to be established.
- Harmful cholesterol levels cut in half with one-time gene editing drug in early trial NBC News
- Scientists have edited a gene that may reduce high cholesterol permanently CNN
- How a ‘one and done’ gene-editing treatment could lower cholesterol The Washington Post
- A Gene Editing Therapy Cut Cholesterol Levels by Half WIRED
- CRISPR gene-editing works to reduce high cholesterol in a new study NPR
Reading Insights
Total Reads
0
Unique Readers
24
Time Saved
5 min
vs 5 min read
Condensed
95%
969 → 44 words
Want the full story? Read the original article
Read on NBC News